The Hyperlipidemia drugs in development market research report provides comprehensive information on the therapeutics under development for Hyperlipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hyperlipidemia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hyperlipidemia and features dormant and discontinued products.
GlobalData tracks 133 drugs in development for Hyperlipidemia by 86 companies/universities/institutes. The top development phase for Hyperlipidemia is preclinical with 40 drugs in that stage. The Hyperlipidemia pipeline has 120 drugs in development by companies and 13 by universities/ institutes. Some of the companies in the Hyperlipidemia pipeline products market are: Addpharma, Kuhnil Pharmaceutical and Suzhou Ribo Life Sciences.
The key targets in the Hyperlipidemia pipeline products market include Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.), 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase (HMG CoA Reductase or Hydroxymethylglutaryl CoA Reductase or HMGCR or EC 1.1.1.34), and Angiopoietin Related Protein 3 (Angiopoietin 5 or Angiopoietin Like Protein 3 or ANG 5 or ANGPTL3).
The key mechanisms of action in the Hyperlipidemia pipeline product include Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) Inhibitor with 11 drugs in Pre-Registration. The Hyperlipidemia pipeline products include four routes of administration with the top ROA being Oral and 14 key molecule types in the Hyperlipidemia pipeline products market including Small Molecule, and Antisense RNAi Oligonucleotide.
Hyperlipidemia overview
Hyperlipidemia is a medical condition characterized by elevated levels of lipids (fats) in the blood. This includes high levels of cholesterol and triglycerides. It is a significant risk factor for cardiovascular diseases, such as atherosclerosis, coronary artery disease, and stroke. Hyperlipidemia can be caused by genetic factors, an unhealthy diet high in saturated fats and cholesterol, sedentary lifestyle, obesity, and certain medical conditions like diabetes mellitus. Diagnosis is typically made through blood tests measuring lipid levels. Treatment involves lifestyle modifications such as a healthy diet, regular exercise, and weight management. Medications, including statins, may be prescribed to lower lipid levels and reduce cardiovascular risk. Regular monitoring is essential for managing hyperlipidemia effectively.
For a complete picture of Hyperlipidemia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
